Literature DB >> 195410

Cytostatic efficacy of DNA-complexes of adriamycin, daunomycin and actinomycin D. I. Comparative studies in Novikoff hepatoma, human mammary carcinoma cells and human leukemic leukocytes.

S Seeber, K P Brucksch, B Seeber, C G Schmidt.   

Abstract

Inhibitory effects of adriamycin, daunomycin, actinomycin D and of the related DNA-complexes on DNA and RNA synthesis were compared by precursor uptake studies in Novikoff hepatoma cells, human mammary carcinoma cells and human leukemia cells. In addition, nuclear RNA labelling profiles were analyzed in human acute leukemia blast cells and nucleolar RNA synthesis was studied in Novikoff hepatoma cells in vitro after incubations of the tumor cells with adriamycin and DNA-adriamycin. The studies revealed that compared to the free drugs a) the DNA complexes were generally less active with respect to inhibition of overall DNA and RNA synthesis in these divergent tumor cell types, b) characteristic differences between adriamycin and daunomycin which are related to a more rapid cellular uptake of daunomycin were still present after complexing of both drugs to calf thymus DNA, and c) the intracellular mode of action of the free antibiotics was not changed by complex formation with DNA. These results indicate that a preferential incorporation of the macromolecular complexes into the tumor cells by pinocytosis--as originally postulated by Trouet et al. (1972)--is not likely for Novikoff hepatoma cells, human mammary carcinoma cells and human acute leukemia blast cells. In contrast, it may be concluded from this study that the DNA complexes dissociate already at the outer cell membrane resulting in a generally decreased but kinetically drug-specific cellular uptake. In a second communication it will be demonstrated that these in-vitro effects do not correlate with the therapeutic efficacy efficacy of the complexed drugs in vivo.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 195410     DOI: 10.1007/bf02571692

Source DB:  PubMed          Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol        ISSN: 0084-5353


  10 in total

1.  Sedimentation characteristics of rapidly labelled RNA from HeLa cells.

Authors:  K SCHERRER; J E DARNELL
Journal:  Biochem Biophys Res Commun       Date:  1962-06-04       Impact factor: 3.575

2.  Structural analysis of nucleolar precursors of ribosomal ribonucleic acid. Polypurine sequences in nucleolar 28 S ribonucleic acid of Novikoff hepatoma ascites cells.

Authors:  S Seeber; Y C Choi; H Busch
Journal:  J Biol Chem       Date:  1971-04-25       Impact factor: 5.157

3.  Experimental leukemia chemotherapy with a "lysosomotropic" adriamycin-DNA complex.

Authors:  A Trouet; D Deprez-de Campeneere; M de Smedt-Malengreaux; G Atassi
Journal:  Eur J Cancer       Date:  1974-07       Impact factor: 9.162

4.  Comparison of adriamycin with the DNA-adriamycin complex in chemotherapy of L1210 leukemia.

Authors:  G Atassi; H J Tagnon
Journal:  Eur J Cancer       Date:  1974-07       Impact factor: 9.162

5.  The stereochemistry of actinomycin binding to DNA.

Authors:  H M Sobell
Journal:  Cancer Chemother Rep       Date:  1974 Jan-Feb

6.  Chemotherapy through lysosomes with a DNA-daunorubicin complex.

Authors:  A Trouet; D Deprez-de Campeneere; C De Duve
Journal:  Nat New Biol       Date:  1972-09-27

7.  Stereochemistry of intercalation: interaction of daunomycin with DNA.

Authors:  W J Pigram; W Fuller; L D Hamilton
Journal:  Nat New Biol       Date:  1972-01-05

8.  Letter: DNA-daunorubicin complex: preliminary trials in human leukaemia.

Authors:  G Sokal; A Trouet; J L Michaux; G Cornu
Journal:  Eur J Cancer       Date:  1973-05       Impact factor: 9.162

9.  Isolation of rapidly labelled nuclear RNA of high specific activity from human leukaemic cells.

Authors:  S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1973-07-01

10.  Potentiation of actinomycin D or adriamycin antitumor activity with DNA.

Authors:  T A Marks; J M Venditti
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

  10 in total
  7 in total

1.  Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex.

Authors:  M Beran; B Andersson; S Eksborg; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.

Authors:  Y J Schneider; R Baurain; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor.

Authors:  T Skovsgaard
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.

Authors:  R Hulhoven; G Sokal; C Harvengt
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.

Authors:  A Trouet; D Deprez-De Campeneere
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.

Authors:  S O Nilsson; B Andersson; S Eksborg; M Beran; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Cystostatic efficacy of DNA-complexes of adriamycin, daunomycin, and actinomycin D. II. Comparative in vivo studies in an Ehrlich-ascites tumor.

Authors:  S Seeber; R B Schilcher; K P Brucksch; J Käding; C G Schmidt
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1977-12-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.